Investigating BRCA2 mutations in breast cancer patients in Reunion
Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2
This study is testing if a specific BRCA2 gene mutation is common in breast cancer patients in Reunion to help improve treatment options for them.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de la Réunion Academic / other |
| Locations | 1 site (Saint-Pierre) |
| Trial ID | NCT05898009 on ClinicalTrials.gov |
What this trial studies
This study focuses on the contribution of oncogenetics to breast cancer in Reunion, specifically examining the prevalence of a unique BRCA2 mutation within the local population. It aims to analyze blood samples from patients diagnosed with breast cancer to detect these mutations and understand their implications for treatment and prognosis. The study is particularly relevant given the rising incidence of breast cancer in Reunion, where over 400 new cases are diagnosed annually. By identifying genetic factors, the research seeks to enhance personalized treatment approaches for affected individuals.
Who should consider this trial
Good fit: Ideal candidates include women diagnosed with their first or second breast cancer who reside in Reunion.
Not a fit: Patients with breast lymphoma or those who are minors or under guardianship will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved genetic screening and targeted therapies for breast cancer patients in Reunion.
How similar studies have performed: Previous studies have shown that a significant portion of patients in Reunion carry a specific BRCA2 mutation, indicating potential for success in this targeted approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Domiciled in Reunion at the time of the diagnosis * Who is diagnosed with a first breast cancer (in situ or invasive) confirmed by anatomopathological examination during the inclusion period Or Who is diagnosed with a second breast cancer (in situ or invasive) confirmed by pathological examination during the inclusion period, contralateral to the first or at least 5 years after remission of the first * Having agreed to participate in the study; * Affiliates or beneficiaries of a social security scheme Exclusion Criteria: * Carriers of breast lymphoma, * Minor patients or patients under guardianship or curatorship
Where this trial is running
Saint-Pierre
- Mireille IRABE — Saint-Pierre, France (Recruiting)
Study contacts
- Study coordinator: Mireille IRABE
- Email: mireille.irabe@chu-reunion.FR
- Phone: 0262906283
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.